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Abstract 
 
Phylogenetics applied to pathogen genetics is an increasingly powerful tool to help reduce the 
spread of epidemics, including HIV. As a result, phylogenetic approaches are becoming embedded in 
public health and research programmes, as well as outbreak responses. This presents unique ethical, 
legal and social issues which are not addressed adequately by the existing bioethics literature.  
 
A multidisciplinary working group was formed to explore the ethical issues arising from the design, 
conduct and use of results from HIV phylogenetic studies, and to propose recommendations to 
minimise the associated risks both to individuals and groups.  
 
We identified eight critical ethical domains within which we highlighted factors that make HIV 
phylogenetic research unique. We also endeavoured to provide a framework to assist researchers, 
public health practitioners, and funding institutions to ensure that HIV phylogenetic studies are 
designed, conducted and disseminated in an ethical manner. Our findings have broader relevance 
for pathogen phylogenetics. 
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Introduction 
Understanding the transmission dynamics of infectious agents is critical to developing effective 
public health interventions. Historically, this was done using epidemiological tracking of the 
evolution of epidemics through time, place and person, based primarily on observation and self-
reports of exposure and risk behaviours. However, despite advances in HIV prevention, HIV 
incidence remains high, notably in sub-Saharan Africa, which accounts for 75% of all new HIV 
infections worldwide (1). In this context, understanding who is most likely to infect whom remains 
an important consideration in the development of targeted prevention strategies.  
 
In phylogenetic analysis historical relationships between individuals or groups are deduced by 
comparing pathogen genomes, establishing how closely related viruses from two individuals are. In 
combination with traditional epidemiological data, these viral genetic sequence data can be thus 
help to infer transmissions patterns. The combination of phylogenetics and traditional epidemiology 
has demonstrated the potential to answer critical questions that are not easily addressed by 
traditional or molecular approaches alone (2-4).  
 
In recent years, the focus of HIV phylogenetic studies has extended from concentrated to 
generalised epidemics, and increasingly involves sizeable datasets (5). Funding bodies such as the 
Wellcome Trust, the Bill & Melinda Gates Foundation, and the National Institutes of Health are 
committed to sharing such datasets to maximise the benefit of HIV research. Additionally, sequence 
data analysed for publications in scientific journals are usually required to be submitted to open 
public sequence repositories. The collection, storage, sharing and research use of such data raises 
important ethical, legal and social challenges.  
 
International ethical guidelines for research with human participants, such as the Helsinki 
Declaration and the Council for International Organizations of Medical Sciences (CIOMS) guidelines 
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address a number of these issues, including the need for informed consent, community engagement, 
risk minimization, and consideration of the risks and benefits of research for groups and 
communities (6, 7).  In addition, a large and diverse academic and policy literature exists addressing 
the ethical, legal and social implications (ELSI) of the research and clinical uses of human genomics in 
high-income countries (HIC)(8). In recent years, this has been accompanied by a growing bioethics 
and social science literature on the implications of genomic research in low- and middle-income 
countries (LMIC)(9-10), and by stakeholder engagement initiatives in these settings (11-13). The key 
documents, position statements and initiatives are summarized in Supplementary Table 1.  
 
HIV phylogenetic research presents complex ethical issues, including two specific challenges. Firstly, 
(like contact tracing data) phylogenetic analyses are fundamentally relational: analysis of data from 
one person may impact other people, for example by identifying them as potential sources of 
infection. Secondly, as sequence data become richer (through next generation sequencing (NGS)), 
true anonymization of viral sequence data becomes difficult, since virus isolated from another time-
point in another study could be used to re-identify an individual. In recognition of this, and of the 
need for the development of models of good ethical practice in this area, we held a multidisciplinary 
(scientists, bioethicists, lawyers, human rights advocates, HIV activists and community engagement 
members from Africa) workshop in London in May 2017 (15). This meeting focused both on 
identifying the critical issues arising from designing, conducting, or using the results of HIV 
phylogenetic studies, and on making recommendations regarding the public release and publishing 
of data obtained from HIV phylogenetic studies in an ethical manner.   
 
This review article summarises the findings and recommendations both from the workshop and 
follow-up discussions, and sets out a framework for both researchers and funding bodies 
undertaking HIV genetic studies. This also has relevance for the increasing use of phylogenetics for 
non-HIV pathogens, including within outbreak response situations.   
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Phylogenetics and its role in HIV research 
Over time and successive generations, mutations occur in the genetic code of species. Phylogenetic 
inference exploits these changes to determine the genetic similarity of two organisms, assuming the 
more similar their genetic sequence, the closer in time they are to having a common ancestor. 
Applying this approach to the HIV detected in blood samples from infected human populations helps 
to understand HIV transmission patterns.  
 
HIV lends itself to phylogenetic analysis as it is highly genetically variable (16). The transmission of 
HIV involves two individuals (a couple) and the variability of HIV is used to infer linkages forming 
phylogenetic clusters between couples and groups of people (17).  In addition, it is possible in many 
cases to infer, with a degree of uncertainty, the direction of transmission within clusters, either by 
using additional epidemiological data (18, 19), or by using data with sequences from multiple viruses 
sampled from each individual (20, 21).  
 
There are different techniques to generate the sequence data required for phylogenetic analysis. 
NGS increases both the potential power and potential risks of phylogenetic approaches compared to 
conventional Sanger sequencing methods (22, 23), as it provides information on intra-host variation, 
and returns richer sequence data on multiple viral particles per sample. Additionally, there are many 
methods and associated assumptions in phylogenetic analyses and a number of methodological 
considerations for identifying clusters of genetically related viruses through phylogenetic analyses 
(Supplementary Box 1). Phylogenetic clusters are generally thought to represent groups of infected 
persons closer together in a transmission chain and can be identified via different methods (3, 24-
28). 
 
Caution is required when interpreting phylogenetic clusters for epidemiological purposes. This is 
because clusters are typically inferred from partially sampled transmission chains, i.e. some infected 
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individuals were not sampled. Unsampled cases may act as either a common source of infection or 
as an intermediary in a transmission chain for hosts infected with genetically similar pathogens. 
Whilst historically it has been difficult clearly to prove transmission between two individuals, the use 
of NGS together with improved interpretation algorithms makes such inferences more likely in 
future.  
 
Phylogenetic analyses can be used widely in HIV epidemiology (see Figure 1 for details). For example, 
they can be used to study viral linkage and risk factors for epidemic spread (molecular epidemiology) 
(4), the growth/decline of the HIV epidemic (phylodynamics) (3, 29, 30), or the impact of migration 
on HIV spread and the identification of hubs of transmission (phylogeography)(31).   
 
HIV phylogenetics has been most applied in HIC with greater scientific infrastructure, where HIV is 
characterised by smaller epidemics, focused on specific risk groups (“concentrated epidemics”). In 
many HIC, sequencing of the HIV pol gene is used to monitor both transmitted drug resistance at 
time of diagnosis and emerging drug resistance on antiretroviral therapy (ART)(32). This has led to 
the growth of national HIV genetic databases, such as in the UK (33) and Switzerland (34). If such 
datasets are linked to epidemiological surveillance and clinical cohort data, inferences may be made 
with regard to patterns of exposure and risk factors for onwards transmission amongst infected 
individuals (18, 29, 35). Unlike standard epidemiological data, molecular data can also allow 
inferences to be made from the time of transmission relative to the time of sample collection. 
Furthermore, the data obtained through phylogenetic analyses can be used to validate self-reported 
epidemiological data in relation to sexual and other behaviours.  Combined with traditional 
epidemiological tools, phylogenetic research provides more detailed and precise understanding of 
epidemic characteristics, thereby enabling improved public health policies, including more effective 
and better targeted programs for prevention and treatment (36, 37).  
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Many African epidemics are much larger than those in the US and Europe. The sequencing of virus in 
Africa is currently not routinely undertaken outside of targeted programmes such as the World 
Health Organisation’s HIV drug resistance surveillance (38) and research projects.  Whilst declining 
cost and progressively easier sequencing will increase the proportion of infected individuals 
represented within sequence databases, such as PANGEA-HIV (5), Africa does not yet have the 
extensive and comprehensive datasets seen in HIC. In addition, community and patient mobilisation 
around HIV takes very different forms compared to that in HIC, and the social, political and economic 
context is significantly different and varies among African countries.  Ethical analysis of phylogenetic 
work will therefore need to take account of international variation in both epidemic characteristics 
and local economic, legal and social contexts.  
 
Key ethical issues arising in phylogenetic studies of HIV transmission 
Some of the ethical issues raised by HIV phylogenetic research are similar to those in traditional 
epidemiology studies. These include the potential for stigmatization and risk of social harm to 
individuals or groups, and concerns about privacy, confidentiality and security of data. However, 
there are risks that are particularly salient in phylogenetic research, which we discuss over eight 
critical ethical domains. 
 
(i) Risk and benefit assessments  
The harms and benefits of phylogenetic research will vary depending on whether they are assessed 
at the individual, group or societal level (Figure 2). Information obtained through phylogenetic 
analyses should be used to advance socially valuable goals, such as reducing the spread of HIV, 
whilst at the same time minimising the risks to individuals, groups, and populations. Of particular 
concern with phylogenetics is that complex social and sexual relationships may be deduced by 
adding minimal clinical and demographic information. In contrast, traditional epidemiological studies 
9 
 
would require far more information in order to draw inferences about transmission of HIV between 
individuals, particularly with respect to directionality of infection.  
 
Risks to individuals principally arise either from inadvertent or intentional disclosure of HIV status or 
transmission events, or from demands for these data for judicial or extra-judicial targeting of 
individuals or groups. In a number of countries, phylogenetic evidence is being used in criminal cases 
of alleged HIV transmission (39-42). Breaches of confidentiality could occur through inadequate 
anonymization or deductive disclosure, through misinterpretation, miscommunication, or misuse of 
the analytic results, or through legal action.  
 
These risks will increase if more data is generated and made publicly available, a requirement of 
many funding agencies and publishers. While publication might maximize the scientific research 
value of a dataset, it raises concerns about how the data are used, appropriate consent for such use, 
confidentiality, and stigma. Furthermore, contrary to epidemiological studies where individuals can 
choose what information they disclose to investigators, inferences made from viral genetic 
sequences are not controlled by participants. 
 
Anonymization may provide some protection to individuals. However, even with anonymization, 
deductive disclosure of identities from HIV sequence and other corresponding data remains 
theoretically possible. Through the use of rich NGS data applied at successive time-points, a virus 
sequenced from an individual could in principle be used to re-link that individual to an earlier study 
with high reliability. Furthermore, small fragments of human DNA sequence contained in NGS data 
could be accidentally released. In addition, human leukocyte antigen of the infected individual is 
imprinted on the virus due to immune selection, which may assist individual identification in the 
future (43). The probability of re-linking individuals to anonymised data can be minimised by 
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processing sequence data prior to release, for example by only including consensus sequences, 
which suffice for many phylogenetic methods.   
 
Notwithstanding these risks, maintaining a link to individuals’ identities may allow for direct benefits 
to individuals. Sequence information can provide clinical guidance, for example, by allowing 
treatment optimization following detection of drug resistance mutations. Indeed, most HIV 
phylogenetic studies to date have used data obtained for clinical drug resistance testing, from 
resistance surveillance programmes, or as part of broader research studies.  
 
At a population level, phylogenetic analysis can allow individuals’ data to be linked to one-another in 
a network, enabling inference about the characteristics of networks and identification of risk groups. 
This information could be used to focus public health interventions towards specific groups at high 
risk of both acquiring and transmitting the infection.  
 
The choice of meta-data variables used in phylogenetic analysis is an important ethical decision. 
Phylogenetic analyses are often based upon individual-level demographic, behavioural or clinical 
variables, ignoring structural and environmental factors. Focusing only on these variables may 
reinforce the perception that certain groups (for example key populations such as men who have sex 
with men (MSM) or people who inject drugs (PWID)) are responsible for infecting others and 
sustaining the HIV epidemic. In contrast, other structural factors, such as those highlighted in the 
case study of migration in Botswana (see Box 1), as well as sexual violence, lack of access to 
prevention and treatment, and having experienced discrimination, may play a significant role in HIV 
transmission (44). Studying these factors and their effect on HIV transmission risk can decrease the 
“blaming mentality” and create alternative understanding of how to reduce HIV transmission, and 
which individuals or groups are most at risk and why. 
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Plans for addressing risks to individuals and to groups should be developed in the planning stages of 
research projects.  For protection of individuals, particularly the risk of criminal prosecution or other 
targeting based on either HIV status or HIV transmission events, anonymization of data provides 
considerable protection.  While it is theoretically possible that individuals could be identified 
through re-analyzing and re-linking anonymized data from different sources, it would be difficult and 
require specialized expertise.  In contrast, datasets with individual identifiers still linked could be 
subpoenaed or obtained through unauthorized means, putting individuals at risk.  
 
Researchers, therefore, need to assess carefully the potential of identifying specific individuals or 
groups of people from their data, whether this identification could provide benefit in informing 
targeted treatment or interventions, and whether these benefits outweigh the risks to individuals 
and groups by being identified. Preference should be given to other approaches that achieve the 
same research objective, but involve less risk. Finally, an ongoing monitoring of anticipated and 
unanticipated risks should be built into HIV phylogenetic research, and mitigation strategies 
identified as early as possible.  
 
(ii) Protection of the rights and interests of study participants while in pursuit of scientific 
progress and improvements to public health  
Effective phylogenetic work often takes place at the interface between research and public health 
practice: the same data can be used for both purposes. Researchers are typically viewed as obliged, 
so far as possible, to protect individuals who enrol in a study from risk of harm while pursuing 
valuable knowledge. In contrast, public health agencies have the mission of protecting the health of 
the public, which sometimes involve overruling individuals’ privacy interests to use data for public 
health decision making.  Where research also has implications for specific population groups, further 
considerations relating to group harm are important (50-52). Some research and clinical challenges 
in phylogenetic analyses are highlighted in Box 2. 
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The obligation of researchers to communicate results to study participants needs to be evaluated for 
each phylogenetic study. Where clinical action is required, there is an obligation to make results 
available.  In general, this goal (and benefit) is currently theoretical because phylogenetic results are 
produced with a significant delay from sampling, and therefore any result would likely no longer be 
timely in informing clinical care. However, with the evolution of real time phylogenetics, reporting of 
drug resistance data to study participants may result in changes to clinical management. A second 
potential issue is the source of HIV acquisition in discordant couples. As outlined in Box 2, it may be 
critical for interpreting the efficacy of prevention strategies to establish whether HIV acquisition 
events are linked to the known infected partner. However, disclosure of these results to study 
participants may result in adverse consequences for the individuals involved (53).   
 
(iii) Local social and legal context, including human rights violations  
Understanding the local social and legal context is crucial to understanding the risks and benefits 
associated with phylogenetic research. For example, whilst certificates of confidentiality are legally 
binding tools to protect both research participants and researchers from being compelled to reveal 
personal data in the US, similar protocols do not exist in many other HIC or in LMIC (54). Knowledge 
of local legal proceedings is therefore essential for ensuring that research data is unavailable to 
subpoena, and thus dramatically reduce the level of individual risk. Furthermore, changes to the 
social and legal environment need to be regularly monitored to ensure that new risks are not 
introduced during the course of the study. Finally, researchers need to be clear with policy-makers 
how proposed laws or policies could negatively impact HIV research efforts and interventions. 
 
The global human right to health (6, 55) encompasses prevention and treatment, and a right to 
privacy, consent, freedom from discrimination and violence, yet persecution of key populations in 
Africa remains widespread (56-58). Research methods have been used to violate individuals’ rights, 
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including the use of key population mapping by police to arrest and harass sex workers and MSM in 
Nigeria in 2014 (59), impose travel bans on foreigners, enforce restrictions on access to housing, 
schooling and employment, and trigger violent attacks, including murder. Box 3 highlights key legal 
and human rights pre-requisites for the use of phylogenetic tools for public health. These are based 
on norms provided under international human rights treaties as well as national constitutions and 
legislation. 
 
Globally, 72 countries (a third of them in Africa) have laws specifically allowing for HIV 
criminalisation (60). Box 4 reviews phylogenetic analysis used in criminal convictions. Government 
officials or other actors may misinterpret, or wilfully misconstrue, the results of phylogenetic 
research in support of political agendas or criminal convictions, putting individuals at risk of criminal 
prosecution for HIV transmission or broader human rights abuses. A realisation from these 
communities of the possible consequences for privacy and prosecution may lead to a reluctance to 
test, failure to disclose contacts and/or refusal of resistance testing. There is evidence that these 
effects have already occurred (61-63). The likelihood of misuse and abuse of these data is high, 
particularly for stigmatised populations. Researchers should alert ethical review committees and 
suspend research when risks to study participants increase.  
 
Misuse of phylogenetic data, including seizing and subpoena of such data by police and in criminal 
proceeding or perceptions by people living with HIV (PLHIV) and members of key populations that 
phylogenetic data might be misused against them, can undermine trust in research projects and 
health care systems, thus putting HIV prevention and treatment programmes at risk. Research 
conducted in countries where privileged information between medical practitioners and their 
patients can be seized in HIV-related criminal trials showed that PLHIV were more reluctant to speak 
openly with their practitioners about their sexual partners and practices (63). These risks can be 
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mitigated in phylogenetic studies by ensuring awareness of and addressing social and legal issues at 
the planning stages and monitoring these throughout the project. 
1 
(iv) Risk mitigation strategies to protect individual and group identities 
Many of the risks relating to identification of individuals from phylogenetic information in 
environments with oppressive laws and policies can be reduced through use of anonymization. 
Therefore, one default presumption is that if scientific objectives can be accomplished with 
anonymized data, this is preferable.  This default presumes there is no overriding interest in 
individuals receiving research results at individual level.  If the data are not relevant for clinical care, 
given, for example, significant time delay between sample collection and generation of sequence 
information, then there is little rationale for returning data to health care workers.  Where sequence 
analysis is timely, resistance data should be returned to clinics before performing phylogenetic 
analyses on anonymised sequencing data. 
 
If anonymization is significantly detrimental to the scientific objectives or public health, further 
ethical analysis must be undertaken and specific steps taken to protect the data from use in harmful 
proceedings.  These steps might be technical (storage linkage to identifiers in coded, separate 
databases with controlled access) and/or legal, for example legal agreements that data will remain 
protected from disclosure for the duration of the study. 
 
The risk that individuals are de-anonymised by use of later samples, for example infected blood 
collected at a different time point as part of a linked unrelated study, or as part of a criminal 
investigation, can be mitigated by restricting the amount of data that is shared. For example, by 
restricting to one virus sequence per individual person, and keeping raw NGS data under managed 
access, or destroying raw data. However, this reduces the potential scientific benefits of the study 
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since it limits the ability to apply newly develop bioinformatic algorithms to infer the direction of 
transmission, for example.  
 
Risks to groups cannot be addressed through anonymization of individuals.  Groups can be placed at 
risk through characterization as high risk or likely to transmit virus, and these can include 
geographically defined groups, as well as sexual or gender minorities, those defined by ethnicity, 
nationality, or migration status.  Mitigation plans to address these risks need to include consultation 
with community representatives, consideration of the public health value of the findings and 
development of communication plans in formats and venues that are least damaging to vulnerable 
groups.  In some cases, detailed findings might need to be communicated confidentially rather than 
publicly; and some group descriptors may need to be masked in research publications and press 
releases. Risk mitigation strategies must also provide for redress mechanisms in cases of abuse or 
misuse of phylogenetic data. These may require the establishment of ties with local legal services 
organizations working to protect PLHIV and criminalized or stigmatized populations to ensure that 
they have access to the means to protect their rights. 
 
Finally, training those involved in phylogenetic research on the potential of harm to communities 
and individuals is an important risk mitigation strategy. Such training should aim to ensure that 
research staff are sensitive to the risk of harm and understand key issues of anonymity, 
confidentiality, informed consent and protection of research participants and communities. 
 
(v) Valid informed consent and other safeguards 
The formal requirements for the achievement of valid consent are well-established in literature and 
guidelines (66). The issues arising in relation to consent for phylogenetic studies are likely to be 
multifaceted. Obtaining community assent (via community leaders) and individual informed consent 
is particularly challenging for complex scientific studies such as phylogenetic research, which involve 
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concepts that are hard to both explain and understand, and have multiple possible risks and 
benefits.  
 
Due to the complex concepts involved, phylogenetic research may raise fears about the aims of the 
work and the implications of participation among research participants, frontline research staff, 
healthcare professionals and ethics committee members. Communication tools which increase the 
understanding of phylogenetic studies need to be designed and evaluated. These must emphasise 
the potential harms, thoughtful mitigation of harms to risk groups, processes for monitoring risk, 
and clear protection procedures to minimise risks. Nevertheless, with ever-advancing technologies, a 
comprehensive “one size fits all” consent model will be hard to design. 
 
Study participants and patients whose samples are being used for phylogenetic analysis should 
ideally have consented to such use. However, sequence data generated from drug resistance testing 
and other surveillance data typically does not include explicit consent to participate in large-scale 
phylogenetics analyses. Data from previous research studies often entails broad consent for HIV-
related research, but rarely involves specific consent for phylogenetics. In such situations, a waiver 
of specific consent may be obtainable from an ethics committee. Waivers of specific consent are 
allowable when samples are no longer linked to identifiers, or where consent was given for sample 
collection for research and storage in future studies, without specific consent for the current 
research.  
 
Independent review of protocols for phylogenetic is also essential for the protection of research 
participants.  The role of local ethics committees is essential for providing local, independent, 
representation for research participants and others affected by the research, as well as ensuring that 
the local context in which researchers and participants are situated is taken into account.   
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(vi) Community engagement 
Community engagement should occur early on in the research design process, ensuring that the 
phylogenetic research is relevant to participating communities and local perspectives are included in 
the design and overall conduct of research studies (67, 68). Meaningful community engagement is 
particularly challenging in research-naïve and low-income communities, and in criminalized or 
socially marginalized populations. Lack of authentic representative structures, low literacy levels 
and/or poverty place these communities at risk of being exploited, especially where research 
involves highly technical elements, such as viral genomics (69, 70).  
 
Nevertheless, this should not limit attempts to maximise engagement. The phylogenetics study team 
of the PopART study (71) in Zambia has performed extensive community engagement in those 
communities in which the study takes place. The process involved obtaining community input in the 
design stages, as well as ongoing consultation and the development of a feedback protocol. 
Community representatives were consulted on the benefits and risks of informing and sharing 
results with entire communities, and on measures of how to avoid stigmatization of or within 
communities. 
  
(vii) Communication  
Scientific inferences are based on probabilities. Understanding and communicating uncertainty is 
key to understanding phylogenetic results: technical complexity or lack of familiarity with methods 
may easily generate a false sense of accuracy and precision. Researchers performing phylogenetic 
analysis must ensure that caveats, such as the fact that inferences are always based on probabilities 
and that methods are based on assumptions, are clearly highlighted in any dissemination, including 
interviews, publications, oral presentations and posters. It is important to note that probabilities 
vary; an assignment of 50% to a transmission event is very different of an assignment of 99%; in both 
cases the analyst will report uncertainty, but the conclusions drawn by most observers will be 
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different. An ethical framework in an area of rapid technological development should prepare for 
the possibility that, in some cases at least, probabilistic assignments will likely improve over time.  
 
Mass media campaigns, as well as reporting on social media, television, radio and in newspapers has 
been a powerful tool, raising awareness about HIV, treatments and prevention, and facilitating 
public health campaigns aiming to change attitudes and behaviours. However, the way the media 
frames HIV and reports study outcomes can affect both the long-term and short-term success of any 
campaigns and may generate unintentional consequences, including a lack of trust in healthcare 
services (72, 73). Any ambiguous or misleading reporting of phylogenetic studies may reduce HIV 
testing rates, increase scepticism about participating in studies, and make risk groups less likely to 
access healthcare. Therefore, it is essential to educate the media, local health care personnel and 
the community about these studies.  
 
Care must be taken especially in reporting findings relevant to specific population subgroups, 
including identifiable geographic areas, population groups that may be stigmatized or targeted by 
government, police, others in the community, or subject to criminal charges.  Researchers will need 
to consider the potential social harms and political impact of findings before deciding exactly what 
information should be publicly shared or published.  
 
(viii)  Equitable data sharing 
Largely as a result of the funders’ requirements, many anonymised HIV sequences are being made 
publicly available via GenBank and LosAlamos. This is advantageous for some research studies, such 
as vaccine development. However, there is a real risk of lack of awareness that every sequence is 
associated with a patient or study participant. Care must be taken to ensure human DNA sequences 
are not inadvertently released with NGS data. Routinely publishing only limited information (such as 
the year of sampling and the country of where the sample are collected) with each sequence would 
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help minimize risk. Any other anonymised information should be provided via a controlled access 
protocol which ensures that the research proposed is scientifically valid, does not pose any risks to 
study participants, and is in line with the informed consent obtained. This would require the 
development of a clear governance plan. 
 
Finally, different participant information sheets and consent forms may allow for different levels of 
data sharing, and laws may differ as to how data may be re-used. Any phylogenetic researcher must 
abide to the levels of sharing outlined in the forms, even if this impacts on the quality of the 
research conducted.  
 
Conclusions and recommendations: 
Phylogenetic analyses, either alone or in combination with linked epidemiological data, is a powerful 
tool with the potential to help reduce the spread of the HIV epidemic. However, an effective and 
sustainable model of good ethical practice in phylogenetic research is required to help minimise the 
risks to individuals/groups participating in studies while optimising the scientific benefits. Whilst a 
one-model approach to address any ethical issues is impractical given the vast variations in studies 
and contexts, this review article highlights several themes we believe are essential to consider in 
order to undertake phylogenetic studies in an ethically responsible manner.  
 
We have clustered the critical issues into eight domains, which provide a framework through which 
to consider them: (i) risk and benefit assessments; (ii) protection of the rights and interests of study 
participants; (iii) local social and legal context, including human rights violations; (iv) risk mitigation 
strategies to protect individual and group identities; (v) valid informed consent and other 
safeguards; (vi) community engagement; (vii) communication and (viii) equitable data sharing. Our 
recommendations for each domain, based on our review of the literature and input from experts, 
are summarized in Box 5. 
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So far, viral sequencing has been effectively restricted to large, highly regulated laboratories. 
Emerging DNA sequencing technologies are more powerful in terms of their applications to 
epidemiology (21), more portable, robust to field conditions, and with lower capital costs (74). HIV 
phylogenetics (and increasingly for other pathogens) may therefore become more widely distributed 
across geographic areas and laboratory types, with widely differing regulatory frameworks. 
Furthermore, as phylogenetics is inherently relational, data are likely to be shared amongst wider 
and looser networks of investigators. While these developments have the potential to promote rapid 
scientific advances, they also pose new challenges for governance, enhancing the utility of 
disseminating clear ethical frameworks and promoting positive social norms.   
 
Any researcher conducting phylogenetic analysis should be aware of the risks such analyses pose 
and undertake steps to mitigate these risks. This is particularly pertinent in LMIC, which often have 
weak governance structures and limited laws to protect vulnerable populations. These issues are 
likely to become more problematic as sequence costs decrease and data become more routinely 
available. Looking forward, real-time phylogenetics may be used more frequently to direct public 
health responses and increasingly form the basis for surveillance programmes. Whatever the 
scenario, the fundamental principle of protecting participating individuals and groups must be 
central to any study design, implementation and reporting of results. 
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Figures 
Figure 1: Applications of phylogenetic analyses 
 
 
*Denotes a potential future use of phylogenetic analyses 
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Figure 2:  Potential benefits (left) and harms (right) associated with HIV phylogenetic analysis 
 
 
 
 
